keyword
MENU ▼
Read by QxMD icon Read
search

mCRPC Blood biomarkers

keyword
https://www.readbyqxmd.com/read/27601596/whole-genomic-copy-number-alterations-in-circulating-tumor-cells-from-men-with-abiraterone-or-enzalutamide-resistant-metastatic-castration-resistant-prostate-cancer
#1
Santosh Gupta, Jing Li, Gabor Kemeny, Rhonda L Bitting, Joshua Beaver, Jason Somarelli, Kathryn E Ware, Simon Gregory, Andrew J Armstrong
PURPOSE: Beyond enumeration, circulating tumor cells (CTCs) can provide genetic information from metastatic cancer that may facilitate a greater understanding of tumor biology and enable a precision medicine approach. EXPERIMENTAL DESIGN: CTCs and paired leukocytes from men with metastatic castration-resistant prostate cancer (mCRPC) were isolated from blood through red cell lysis, CD45 depletion, and flow sorting based on EpCAM/CD45 expression. We next performed whole genomic copy number analysis of CTCs and matched patient leukocytes (germline) using array-based comparative genomic hybridization (aCGH) from 16 men with mCRPC, including longitudinal and sequential CTCs aCGH analyses in the context of enzalutamide therapy...
September 6, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27436429/ar-v7-transcripts-in-whole-blood-rna-of-patients-with-metastatic-castration-resistant-prostate-cancer-correlate-with-response-to-abiraterone-acetate
#2
Tilman Todenhöfer, Arun Azad, Craig Stewart, Jian Gao, Bernhard J Eigl, Martin E Gleave, Anthony M Joshua, Peter C Black, Kim N Chi
PURPOSE: The expression of AR-V7 (androgen receptor splice variant) 7 in circulating tumor cells has been associated with resistance to abiraterone and enzalutamide in patients with metastatic castration resistant prostate cancer. We used a sensitive, whole blood reverse transcriptase-polymerase chain reaction assay that does not require circulating tumor cell enrichment to correlate outcomes of abiraterone with whole blood expression of AR-V7 and other prostate cancer associated transcripts...
July 17, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27262168/association-of-ar-v7-on-circulating-tumor-cells-as-a-treatment-specific-biomarker-with-outcomes-and-survival-in-castration-resistant-prostate-cancer
#3
Howard I Scher, David Lu, Nicole A Schreiber, Jessica Louw, Ryon P Graf, Hebert A Vargas, Ann Johnson, Adam Jendrisak, Richard Bambury, Daniel Danila, Brigit McLaughlin, Justin Wahl, Stephanie B Greene, Glenn Heller, Dena Marrinucci, Martin Fleisher, Ryan Dittamore
Importance: A critical decision in the management of metastatic castration-resistant prostate cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a taxane. Objective: To determine if pretherapy nuclear androgen-receptor splice variant 7 (AR-V7) protein expression and localization on circulating tumor cells (CTCs) is a treatment-specific marker for response and outcomes between ARS inhibitors and taxanes. Design, Setting, and Participants: For this cross-sectional cohort study at Memorial Sloan Kettering Cancer Center, 265 men with progressive mCRPC undergoing a change in treatment were considered; 86 were excluded because they were not initiating ARS or taxane therapy; and 18 were excluded for processing time constraints, leaving 161 patients for analysis...
November 1, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/26975354/gene-expression-analysis-of-bone-metastasis-and-circulating-tumor-cells-from-metastatic-castrate-resistant-prostate-cancer-patients
#4
Won Jin Cho, Daniel S M Oliveira, Abdo J Najy, Leandro E Mainetti, Hussein D Aoun, Michael L Cher, Elisabeth Heath, Hyeong-Reh C Kim, R Daniel Bonfil
BACKGROUND: Characterization of genes linked to bone metastasis is critical for identification of novel prognostic or predictive biomarkers and potential therapeutic targets in metastatic castrate-resistant prostate cancer (mCRPC). Although bone marrow core biopsies (BMBx) can be obtained for gene profiling, the procedure itself is invasive and uncommon practice in mCRPC patients. Conversely, circulating tumor cells (CTCs), which are likely to stem from bone metastases, can be isolated from blood...
2016: Journal of Translational Medicine
https://www.readbyqxmd.com/read/26960325/automated-bone-scan-index-as-a-quantitative-imaging-biomarker-in-metastatic-castration-resistant-prostate-cancer-patients-being-treated-with-enzalutamide
#5
Aseem Anand, Michael J Morris, Steven M Larson, David Minarik, Andreas Josefsson, John T Helgstrand, Peter S Oturai, Lars Edenbrandt, Martin Andreas Røder, Anders Bjartell
BACKGROUND: Having performed analytical validation studies, we are now assessing the clinical utility of the upgraded automated Bone Scan Index (BSI) in metastatic castration-resistant prostate cancer (mCRPC). In the present study, we retrospectively evaluated the discriminatory strength of the automated BSI in predicting overall survival (OS) in mCRPC patients being treated with enzalutamide. METHODS: Retrospectively, we included patients who received enzalutamide as a clinically approved therapy for mCRPC and had undergone bone scan prior to starting therapy...
December 2016: EJNMMI Research
https://www.readbyqxmd.com/read/26948395/tmprss2-erg-in-blood-and-docetaxel-resistance-in-metastatic-castration-resistant-prostate-cancer
#6
Òscar Reig, Mercedes Marín-Aguilera, Gemma Carrera, Natalia Jiménez, Laia Paré, Susana García-Recio, Lydia Gaba, Maria Verónica Pereira, Pedro Fernández, Aleix Prat, Begoña Mellado
: TMPRSS2-ERG rearrangement is a genetic alteration exclusive to prostate cancer, associated with taxane resistance in preclinical models. Its detection in blood samples of metastatic resistant prostate cancer (mCRPC) patients may indicate the presence of circulating tumour cells with this genetic alteration and may predict taxane resistance. To test this hypothesis, we evaluated TMPRSS2-ERG expression using quantitative reverse transcription polymerase chain reaction in peripheral blood mononuclear cells and tumour tissue from mCPRC patients treated with taxanes...
February 29, 2016: European Urology
https://www.readbyqxmd.com/read/26497689/combination-of-circulating-tumor-cell-enumeration-and-tumor-marker-detection-in-predicting-prognosis-and-treatment-effect-in-metastatic-castration-resistant-prostate-cancer
#7
Kun Chang, Yun-Yi Kong, Bo Dai, Ding-Wei Ye, Yuan-Yuan Qu, Yue Wang, Zhong-Wei Jia, Gao-Xiang Li
Although circulating tumor cell (CTC) enumeration in peripheral blood has already been validated as a reliable biomarker in predicting prognosis in metastatic castration-resistant prostate cancer (mCRPC), patients with favorable CTC counts (CTC < 5/7.5 ml) still experience various survival times. Assays that can reduce patients' risks are urgently needed. In this study, we set up a real-time quantitative polymerase chain reaction (RT-qPCR) method to detect epithelial-mesenchymal transition (EMT) and stem cell gene expression status in peripheral blood to validate whether they could complement CTC enumeration...
December 8, 2015: Oncotarget
https://www.readbyqxmd.com/read/25424879/quantitative-characterization-of-androgen-receptor-protein-expression-and-cellular-localization-in-circulating-tumor-cells-from-patients-with-metastatic-castration-resistant-prostate-cancer
#8
Edwin E Reyes, David J VanderWeele, Masis Isikbay, Ryan Duggan, Alexa Campanile, Walter M Stadler, Donald J Vander Griend, Russell Z Szmulewitz
BACKGROUND: Many current therapies for metastatic castration-resistant prostate cancer (mCRPC) are aimed at AR signaling; however, resistance to these therapies is inevitable. To personalize CRPC therapy in an individual with clinical progression despite maximal AR signaling blockade, it is important to characterize the status of AR activity within their cancer. Biopsies of bone metastases are invasive and frequently fail to yield sufficient tissue for further study. Evaluation of circulating tumor cells (CTCs) offers an alternative, minimally invasive mechanism to characterize and study late-stage disease...
2014: Journal of Translational Medicine
https://www.readbyqxmd.com/read/25368278/circulating-tumor-cells-as-a-biomarker-predictive-of-sensitivity-to-docetaxel-chemotherapy-in-patients-with-castration-resistant-prostate-cancer
#9
Takatsugu Okegawa, Naoshi Itaya, Hidehiko Hara, Mitsuhiro Tambo, Kikuo Nutahara
AIM: We examined whether Circulating Tumor Cells (CTCs) can be used to predict survival in patients with bone-metastatic castration-resistant-prostate cancer (mCRPC) treated with docetaxel chemotherapy. PATIENTS AND METHODS: All patients with mCRPC who had experienced treatment failure with androgen deprivation therapy and had received docetaxel chemotherapy were eligible for study inclusion. CTCs in whole blood were enumerated with the CellSearch System. RESULTS: The median CTC count at baseline before starting trial treatment was 7 (range=0-227) CTCs per 7...
November 2014: Anticancer Research
https://www.readbyqxmd.com/read/25219358/circulating-tumor-cell-telomerase-activity-as-a-prognostic-marker-for-overall-survival-in-swog-0421-a-phase-iii-metastatic-castration-resistant-prostate-cancer-trial
#10
RANDOMIZED CONTROLLED TRIAL
Amir Goldkorn, Benjamin Ely, Catherine M Tangen, Yu-Chong Tai, Tong Xu, Hongli Li, Przemyslaw Twardowski, Peter J Van Veldhuizen, Neeraj Agarwal, Michael A Carducci, J Paul Monk, Mark Garzotto, Philip C Mack, Primo Lara, Celestia S Higano, Maha Hussain, Nicholas J Vogelzang, Ian M Thompson, Richard J Cote, David I Quinn
Circulating tumor cells (CTC) are promising biomarkers in metastatic castration resistant prostate cancer (mCRPC), and telomerase activity (TA) is a recognized cancer marker. Therefore, we hypothesized that CTC TA may be prognostic of overall survival (OS) in mCRPC. To test this, we used a novel Parylene-C slot microfilter to measure live CTC TA in S0421, a phase III SWOG-led therapeutic trial. Blood samples underwent CTC capture and TA measurement by microfilter, as well as parallel enumeration by CellSearch (Janssen/J&J)...
April 15, 2015: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/25189164/a-transient-increase-in-eosinophils-is-associated-with-prolonged-survival-in-men-with-metastatic-castration-resistant-prostate-cancer-who-receive-sipuleucel-t
#11
RANDOMIZED CONTROLLED TRIAL
Douglas G McNeel, Thomas A Gardner, Celestia S Higano, Philip W Kantoff, Eric J Small, Mark H Wener, Robert B Sims, Todd DeVries, Nadeem A Sheikh, Robert Dreicer
Sipuleucel-T is an autologous cellular immunotherapy used to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Traditional short-term indicators of clinical response commonly used with chemotherapy have not correlated with survival in patients treated with sipuleucel-T. This retrospective study aimed to evaluate laboratory parameters as possible early biomarkers associated with clinical benefit following sipuleucel-T treatment. Patients treated with sipuleucel-T from three randomized, controlled, phase III clinical trials in mCRPC were considered: IMPACT (NCT00065442; n = 512), D9901 (NCT00005947; n = 127), and D9902A (NCT01133704; n = 98)...
October 2014: Cancer Immunology Research
https://www.readbyqxmd.com/read/25065737/nanomechanical-biomarkers-of-single-circulating-tumor-cells-for-detection-of-castration-resistant-prostate-cancer
#12
Pawel Osmulski, Devalingam Mahalingam, Maria E Gaczynska, Joseph Liu, Susan Huang, Aaron M Horning, Chiou-Miin Wang, Ian M Thompson, Tim H-M Huang, Chun-Liang Chen
BACKGROUND: Emerging evidence shows that nanomechanical phenotypes of circulating tumor cells (CTC) could become potential biomarkers for metastatic castration resistant prostate cancer (mCRPC). METHODS: To determine the nanomechanical phenotypes of CTCs we applied atomic force microscopy (AFM) employing the PeakForce quantitative nanomechanical (QNM) imaging. We assessed biophysical parameters (elasticity, deformation, and adhesion) of 130 CTCs isolated from blood samples from five castration sensitive (CS) and 12 castration resistant prostate cancer (CRPCa) patients...
September 2014: Prostate
https://www.readbyqxmd.com/read/23954088/analytic-and-clinical-validation-of-a-prostate-cancer-enhanced-messenger-rna-detection-assay-in-whole-blood-as-a-prognostic-biomarker-for-survival
#13
Daniel C Danila, Aseem Anand, Nikolaus Schultz, Glenn Heller, Mingliang Wan, Clifford C Sung, Charles Dai, Raya Khanin, Martin Fleisher, Hans Lilja, Howard I Scher
BACKGROUND: Biomarkers based on detecting prostate cancer (PCa)-specific transcripts in blood are associated with inferior outcomes, but their validation in a clinical context is lacking. OBJECTIVE: To determine whether detecting enhanced transcripts for PCa in whole blood using an analytically valid assay has prognostic significance relative to circulating tumor cell (CTC) enumeration. DESIGN, SETTING, AND PARTICIPANTS: The detection of KLK3, KLK2, HOXB13, GRHL2, and FOXA1 in whole blood by reverse transcription polymerase chain reaction (RT-PCR) was studied in 97 men with metastatic castration-resistant PCa (mCRPC) as a prognostic factor for overall survival...
June 2014: European Urology
https://www.readbyqxmd.com/read/22052531/discovery-of-circulating-micrornas-associated-with-human-prostate-cancer-using-a-mouse-model-of-disease
#14
Luke A Selth, Scott Townley, Joanna L Gillis, Aleksandra M Ochnik, Krisna Murti, Robyn J Macfarlane, Kim N Chi, Villis R Marshall, Wayne D Tilley, Lisa M Butler
Circulating microRNAs (miRNAs) are emerging as useful non-invasive markers of disease. The objective of this study was to use a mouse model of prostate cancer as a tool to discover serum miRNAs that could be assessed in a clinical setting. Global miRNA profiling identified 46 miRNAs at significantly altered levels (p ≤ 0.05) in the serum of TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice with advanced prostate cancer compared to healthy controls. A subset of these miRNAs with known human homologues were validated in an independent cohort of mice and then measured in serum from men with metastatic castration-resistant prostate cancer (mCRPC; n = 25) or healthy men (n = 25)...
August 1, 2012: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/21705286/circulating-tumor-cells-as-a-predictive-biomarker-in-patients-with-hormone-sensitive-prostate-cancer
#15
Oscar B Goodman, James T Symanowski, Aida Loudyi, Louis M Fink, David C Ward, Nicholas J Vogelzang
UNLABELLED: Little information exists regarding the utility circulating tumor cell (CTC) enumeration in hormone sensitive prostate cancer. We enumerated CTC in 33 consecutive patients undergoing androgren deprivation therapy (ADT) at our institution. Multivariate analysis revealed baseline CTC as the only independent predictor of progression to CRPC. These data suggest that baseline CTC may identify those unlikely to benefit from ADT. INTRODUCTION: Circulating tumor cell (CTC) enumeration by using the Cellsearch platform has established prognostic and predictive value in patients with metastatic castration-resistant prostate cancer (mCRPC)...
September 2011: Clinical Genitourinary Cancer
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"